XENO-BLOGS

JOURNAL OF BURN CARE & RESEARCH

We're starting 2020 off right with Xeno-Skin's positive preclinical findings published in the American Burn Association's Journal of Burn Care & Research. One study found that Xeno-Skin showed adherence, vascularity, and survival until post-operative day 30 without immunosuppressive drugs, twice the length of similar models in previously published findings. A second study demonstrated Xeno-Skin’s ability to be cryopreserved for up to seven years with no measurable loss in cell viability.

  • Healthy survival until post-operative day 30 without immunosuppressive drugs

  • Cryopreservation capability of 7 years

  • Tremendous promise for #burnsurvivors around the world

Both papers strongly suggest that cryopreserved Xeno-Skin represents a therapeutic with potential significant advantages to the current standard of care, human allograft.

IRB UPDATE

On February 28, 2019, XenoTherapeutics received unconditional approval from the Massachusetts General Hospital (MGH) Institutional Review Board (IRB) to begin enrolling patients for a first-in-human xenotransplantation clinical study to assess the safety and tolerability of Xeno-Skin™ for the treatment of deep partial- and full-thickness burn wounds. Clearing this final hurdle is not only a major milestone for our company but for the field as well; for 40 years, xenotransplantation has been regarded as a solution for future generations, but it is quickly becoming a reality for those in need now. This year, human patients will experience the efficacy of humanized porcine skin, which has been shown in preclinical studies to last as long as traditional human cadaver tissue in providing temporary coverage and restoring barrier functions prior to full wound closure. XenoTherapeutics has worked tirelessly to reach this opportunity and will spend most of this year enrolling candidates and guiding each through successful surgical procedures on site at MGH.

WE'RE HEADED TO VEGAS!

On April 4th, 2019, XenoTherapeutics co-founder Paul Holzer will attend the American Burn Association’s 51st annual meeting in Las Vegas to accept the ABA Burke/Yannas Bioengineering Best Paper Award, which is given for original research studies in the field of bioengineering and honors Dr. John F. Burke and Dr. Ioannis V. Yannas, who were both instrumental in the development of the first artificial skin. In 2018, XenoTherapeutics submitted Cryopreserved Gal-Knockout Xenografts Provide Efficacious Temporary Cover for consideration, which reports that humanized swine tissue, when properly stored, frozen up to 7 years and then thawed for surgery, performs as strongly as human allograft tissue in providing a temporary barrier and delaying rejection prior to full wound closure. Proven data demonstrate essential levels of cellular viability, and by de-animalizing the source animals via selective breeding, Xeno-Skin™ is able to survive for up to 30 days with no instance of cross-species contamination, allowing wounds beneath to fully close. XenoTherapeutics is honored by the ABA’s recognition and look forward to upcoming opportunities to share our discovery with other scientific colleagues in the field of regenerative medicine.

JOIN OUR MAILING LIST

STAY INFORMED & NEVER MISS AN UPDATE
WE'RE HEADED TO VEGAS!

On April 4th, 2019, XenoTherapeutics co-founder Paul Holzer will attend the American Burn Association’s 51st annual meeting in Las Vegas to accept the ABA Burke/Yannas Bioengineering Best Paper Award, which is given for original research studies in the field of bioengineering and honors Dr. John F. Burke and Dr. Ioannis V. Yannas, who were both instrumental in the development of the first artificial skin. In 2018, XenoTherapeutics submitted Cryopreserved Gal-Knockout Xenografts Provide Efficacious Temporary Cover for consideration, which reports that humanized swine tissue, when properly stored, frozen up to 7 years and then thawed for surgery, performs as strongly as human allograft tissue in providing a temporary barrier and delaying rejection prior to full wound closure. Proven data demonstrate essential levels of cellular viability, and by de-animalizing the source animals via selective breeding, Xeno-Skin™ is able to survive for up to 30 days with no instance of cross-species contamination, allowing wounds beneath to fully close. XenoTherapeutics is honored by the ABA’s recognition and look forward to upcoming opportunities to share our discovery with other scientific colleagues in the field of regenerative medicine.